Abstract
Antiretroviral therapy (ART) is the standard of care to treat human immunodeficiency (HIV). However, evidence suggests that delaying the initiation of ART increases the incidence of HIV by contributing to its transmission. The objective of this study was to assess, from a Canadian perspective, the potential epidemiological and economic impact of rapid initiation of HIV treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) compared to current initiation in clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
